Natco Pharma Intrinsic Value
Natco Pharma (NATCOPHARM) median intrinsic value is ₹2351.60 from 9 valuation models (range ₹741–₹2940), vs current price ₹1175.80 — +100.0% upside (Trading Below Calculated Value), margin of safety 50.0%. Browse NATCOPHARM financial statements for revenue, profit, balance sheet and cash flow data.
NATCOPHARM Valuation Methods Summary — DCF, Graham Number & P/E
Natco Pharma intrinsic value across 9 models vs current price ₹1175.80 — upside/downside and value range per method. Also explore NATCOPHARM price trends to track price trends across different timeframes.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹2546.72 | ₹2037.38 - ₹3056.06 | +116.6% | EPS: ₹115.76, Sector P/E: 22x |
| Book Value Method | asset | ₹2939.50 | ₹2645.55 - ₹3233.45 | +150.0% | Book Value/Share: ₹2114.44, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹2351.60 | ₹2116.44 - ₹2586.76 | +100.0% | Revenue/Share: ₹1625.56, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹2351.60 | ₹2116.44 - ₹2586.76 | +100.0% | EBITDA: ₹2716.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹2939.50 | ₹2351.60 - ₹3527.40 | +150.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹740.86 | ₹666.77 - ₹814.95 | -37.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹1788.49 | ₹1609.64 - ₹1967.34 | +52.1% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹2351.60 | ₹2116.44 - ₹2586.76 | +100.0% | ROE: 27.2%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹2346.76 | ₹2112.08 - ₹2581.44 | +99.6% | EPS: ₹115.76, BVPS: ₹2114.44 |
NATCOPHARM Intrinsic Value vs Market Price — All Valuation Models
Natco Pharma fair value range ₹741–₹2940 vs current market price ₹1175.80 across 9 valuation models. For current market price and key ratios, visit Natco Pharma screener.
NATCOPHARM Intrinsic Value Analysis — Undervalued or Overvalued?
Natco Pharma median intrinsic value ₹2351.60, current price ₹1175.80 — Trading Below Calculated Value by 100.0%, margin of safety 50.0%.
What is the intrinsic value of NATCOPHARM?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Natco Pharma (NATCOPHARM) is ₹2351.60 (median value). With the current market price of ₹1175.80, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹740.86 to ₹2939.50, indicating ₹740.86 - ₹2939.50.
Is NATCOPHARM undervalued or overvalued?
Based on our multi-method analysis, Natco Pharma (NATCOPHARM) appears to be trading below calculated value by approximately 100.0%.
NATCOPHARM Financial Health — Key Ratios vs Industry Benchmarks
Natco Pharma financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 70.27 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 27.2% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 42.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.68x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
NATCOPHARM Cash Flow Quality — Operating & Free Cash Flow
Natco Pharma operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹1,697 Cr | ₹979 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹1,212 Cr | ₹699 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹849 Cr | ₹617 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹47 Cr | ₹47 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹299 Cr | ₹246 Cr | Positive Free Cash Flow | 8/10 |